Document:EU GVP: Module XVI EMA/204715/2012 Rev. 3 (2024): Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
Migrate to Template:DocumentData for PageForms (GxPlexBot) Â |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{DocumentData | |||
 | |||
 | |||
|reference=EUÂ GVP: Module XVI | |reference=EUÂ GVP: Module XVI | ||
EMA/204715/2012Â Rev. 3 (2024) | EMA/204715/2012Â Rev. 3 (2024) | ||
Latest revision as of 12:54, 16 July 2026
| Document information | |
|---|---|
| Reference | EU GVP: Module XVI
EMA/204715/2012 Rev. 3 (2024) |
| Validity area | EU |
| Scope(s) | G |
| Document name | GVP: Module XVI
EMA/204715/2012 |
| Version / Revision | Rev. 3 (2024) |
| Status | Current |
| Document type | Official guideline |
| Language(s) | EN |
| Description | Guideline on good pharmacovigilance practices (GVP)
Module XVI – Risk minimisation measures (Rev 3) (Including NIS) |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
References
No references yet.
